SEARCH:   Advanced

Blood, 15 June 2007, Vol. 109, No. 12, pp. 5439-5446. Prepublished online as a Blood First Edition Paper on February 27, 2007; DOI 10.1182/blood-2006-11-058040. This Article Full Text Full Text (PDF) Supplemental Tables and Figure All Versions of this Article: blood-2006-11-058040v1 109/12/5439    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cerhan, J. R. Articles by Hartge, P. Search for Related Content PubMed PubMed Citation Articles by Cerhan, J. R. Articles by Hartge, P. Related Collections Immunobiology Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival James R. Cerhan1, Sophia Wang2, Matthew J. Maurer1, Stephen M. Ansell1, Susan M. Geyer1, Wendy Cozen3, Lindsay M. Morton2, Scott Davis4, Richard K. Severson5, Nathaniel Rothman2, Charles F. Lynch6, Sholom Wacholder2, Stephen J. Chanock2, Thomas M. Habermann1, and Patricia Hartge2 1 Mayo Clinic College of Medicine, Rochester, MN; 2 National Cancer Institute, Bethesda, MD; 3 University of Southern California, Los Angeles; 4 Fred Hutchinson Cancer Research Center, Seattle, WA; 5 Karmanos Cancer Institute, Detroit, MI; and 6 The University of Iowa, Iowa City Recent gene-expression data have suggested that host immune genetic signatures may predict outcomes in patients with follicular lymphoma. We evaluated the hypothesis that germ line common variation in candidate immune genes is associated with survival. Cox models were used to estimate hazard ratios (HR) and corresponding 95% confidence intervals for individual SNPs after accounting for age, clinical, and other demographic factors. The median age at diagnosis of the 278 patients was 57 years, and 59 (21%) of the patients died during follow-up, with a median follow-up of 59 months (range, 27-78 months) for surviving patients. SNPs in IL8 (rs4073; HRTT = 2.14, 1.26-3.63), IL2 (rs2069762; HRGT/TT = 1.80, 1.06-3.05), IL12B (rs3212227; HRAC/CC = 1.83, 1.06-3.06), and IL1RN (rs454078; HRAA = 1.93, 1.11-3.34) were the most robust predictors of survival. A summary score of the number of deleterious genotypes from these genes was strongly associated with survival (P = .001). A risk score that combined the 4 SNPs with the clinical and demographic factors was even more strongly associated with survival (P < .001); the 5-year Kaplan-Meier survival estimates were 96% (93%-100%), 72% (62%-83%), and 58% (48%-72%) for groups at low, intermediate, and high risk, respectively. Common variation in host immune genes warrants further evaluation as a promising class of prognostic factors in follicular lymphoma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. J. Novak, S. L. Slager, Z. S. Fredericksen, A. H. Wang, M. M. Manske, S. Ziesmer, M. Liebow, W. R. Macon, S. R. Dillon, T. E. Witzig, et al. Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma Cancer Res., May 15, 2009; 69(10): 4217 - 4224. [Abstract] [Full Text] [PDF] L. M. Morton, M. P. Purdue, T. Zheng, S. S. Wang, B. Armstrong, Y. Zhang, I. Menashe, N. Chatterjee, S. Davis, Q. Lan, et al. Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1259 - 1270. [Abstract] [Full Text] [PDF] Y. H. Park, S. K. Sohn, J. G. Kim, M.-H. Lee, H. S. Song, M. K. Kim, J. S. Jung, J.-J. Lee, H. J. Kim, and D. H. Kim Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy Clin. Cancer Res., March 15, 2009; 15(6): 2107 - 2115. [Abstract] [Full Text] [PDF] X. Chen, S. Han, S. Wang, X. Zhou, M. Zhang, J. Dong, X. Shi, N. Qian, X. Wang, Q. Wei, et al. Interactions of IL-12A and IL-12B Polymorphisms on the Risk of Cervical Cancer in Chinese Women Clin. Cancer Res., January 1, 2009; 15(1): 400 - 405. [Abstract] [Full Text] [PDF] K. R. Calvo, B. Dabir, A. Kovach, C. Devor, R. Bandle, A. Bond, J. H. Shih, and E. S. Jaffe IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma Blood, November 1, 2008; 112(9): 3818 - 3826. [Abstract] [Full Text] [PDF] T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era Blood, October 1, 2008; 112(7): 2694 - 2702. [Abstract] [Full Text] [PDF] M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF] N. A. Johnson and R. D. Gascoyne Gene expression signatures in follicular lymphoma: are they ready for the clinic? Haematologica, July 1, 2008; 93(7): 982 - 987. [Full Text] [PDF] J. M. Vose Maintenance Rituximab-Should It Be Given to Every Patient with Follicular Lymphoma? ASCO Educational Book, January 1, 2008; 2008(1): 386 - 390. [Abstract] [Full Text] [PDF] G. A. Salles Clinical Features, Prognosis and Treatment of Follicular Lymphoma Hematology, January 1, 2007; 2007(1): 216 - 225. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020